Highlights
- Market Cap
- $10.01M
- Enterprise Value
- $21.62M
- EPS (TTM)
- -$0.29
- Total Revenue (TTM)
- $1.18M
- Gross Profit (TTM)
- $887.57K
- EBITDA (TTM)
- -$1.67M
- Year Range
- $2.25 - $7.77
- ROA (TTM)
- -2.89%
- ROE (TTM)
- -6.51%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in BioLineRx Ltd., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
BioLineRx Ltd. (BLRX) has returned -16.96% so far this year and -22.29% over the past 12 months. Over the last ten years, BLRX has returned -42.61% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
BioLineRx Ltd.
- 1D
- 2.23%
- 1M
- -18.72%
- YTD
- -16.96%
- 6M
- -39.15%
- 1Y
- -22.29%
- 3Y*
- -59.82%
- 5Y*
- -54.19%
- 10Y*
- -42.61%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jul 27, 2011, BLRX's average daily return is -0.07%, while the average monthly return is -1.99%.
Historically, 40% of months were positive and 60% were negative. The best month was Jan 2013 with a return of +87.4%, while the worst month was Jan 2025 at -58.4%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 8 months.
On a daily basis, BLRX closed higher 43% of trading days. The best single day was Jan 24, 2012 with a return of +68.7%, while the worst single day was Mar 20, 2013 at -52.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.27% | -9.00% | -18.72% | -16.96% | |||||||||
| 2025 | -58.41% | -5.90% | -11.64% | 17.23% | 51.30% | -12.95% | -12.91% | -4.77% | -0.26% | -8.20% | 0.00% | -20.17% | -67.64% |
| 2024 | -24.20% | 11.76% | -15.79% | -40.23% | 11.38% | -23.56% | 37.81% | -17.63% | -17.13% | -23.48% | -26.86% | -28.67% | -86.37% |
| 2023 | 6.76% | -5.54% | 48.99% | 20.70% | 47.20% | 1.27% | -3.45% | 13.64% | 4.00% | -17.58% | -3.33% | 8.28% | 166.10% |
| 2022 | -10.78% | -16.48% | 12.50% | -28.65% | 27.87% | -17.95% | 3.12% | 15.15% | -39.14% | -8.41% | -16.80% | -16.30% | -71.08% |
| 2021 | 10.71% | 10.75% | -9.71% | 12.54% | -8.92% | -1.75% | 14.95% | -11.15% | -4.18% | 3.27% | -7.39% | -22.43% | -19.05% |
Benchmark Metrics
BioLineRx Ltd. has an annualized alpha of -22.90%, beta of 0.68, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since July 28, 2011.
- This stock participated in 197.61% of S&P 500 Index downside but only -30.11% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.68 may look defensive, but with R² of 0.02 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -22.90%
- Beta
- 0.68
- R²
- 0.02
- Upside Capture
- -30.11%
- Downside Capture
- 197.61%
Return for Risk
Risk / Return Rank
BLRX ranks 29 for risk / return — below 29% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BioLineRx Ltd. (BLRX) and compare them to a chosen benchmark (S&P 500 Index).
| BLRX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.29 | 0.90 | -1.18 |
Sortino ratioReturn per unit of downside risk | 0.07 | 1.39 | -1.31 |
Omega ratioGain probability vs. loss probability | 1.01 | 1.21 | -0.20 |
Calmar ratioReturn relative to maximum drawdown | -0.40 | 1.40 | -1.80 |
Martin ratioReturn relative to average drawdown | -0.65 | 6.61 | -7.25 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore BLRX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the BioLineRx Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BioLineRx Ltd. was 99.93%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current BioLineRx Ltd. drawdown is 99.93%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.93% | Jan 25, 2012 | 3565 | Mar 30, 2026 | — | — | — |
| -49.41% | Aug 2, 2011 | 29 | Sep 12, 2011 | 92 | Jan 24, 2012 | 121 |
| -5.77% | Jul 28, 2011 | 1 | Jul 28, 2011 | 1 | Jul 29, 2011 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BioLineRx Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BioLineRx Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BLRX relative to other companies in the Biotechnology industry. Currently, BLRX has a P/S ratio of 8.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BLRX in comparison with other companies in the Biotechnology industry. Currently, BLRX has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |